	US 11,946,105 B2
	Bacterial etiology of colorectal cancer
Matthew Meyerson, Concord, MA (US); and Aleksandar Kostic, Brookline, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Jun. 11, 2021, as Appl. No. 17/345,311.
Application 17/345,311 is a division of application No. 14/054,494, filed on Oct. 15, 2013, granted, now 11,060,148.
Claims priority of provisional application 61/714,624, filed on Oct. 16, 2012.
Prior Publication US 2022/0170104 A1, Jun. 2, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/689 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 1/689 (2013.01)]

4 Claims

1. A method of treating colorectal cancer in a subject in need thereof, the method comprising:

a) obtaining a sample from a subject who has colorectal cancer;

b) detecting a level of Fusobacteria in the sample;

c) administering an effective amount of an antibiotic to the subject if the level of Fusobacteria in the sample is higher than a reference level of Fusobacteria obtained from a subject without a Fusobacteria infection; and

d) delaying progression or development of colorectal cancer in the subject by decreasing the level of Fusobacteria in the subject.